43rd Annual Miami Breast Cancer Conference® - Abstracts

PREDICT II is a prospective 30-site observational registry enrolling 3000 women with DCIS to evaluate how a 7-gene biosignature (DCISionRT) impacts treatment recommendations for surgery, radiation, and hormonal therapy.

In this randomized trial, adding a pictorial COPE photo guide to standard verbal counseling for breast cancer patients receiving adjuvant RT led to the only statistically significant improvement in post-treatment skin change scores, with modest non-significant trends toward reduced anxiety.

This narrative review summarizes existing literature and clinical trial data on metastasis-directed and locoregional therapy for oligometastatic and oligoprogressive metastatic breast cancer, highlighting special scenarios where MDT may improve outcomes.

This phase 1/2 trial assessed HER2 BATs combined with pembrolizumab in metastatic breast cancer, finding the regimen safe and well tolerated with stable disease as the best response in 17 evaluable patients.

T-DXd demonstrated a real-world overall response rate of 56.3%, median rwPFS of 7.4 months, and 12-month OS of 62% in patients with HER2-low metastatic breast cancer treated across US community oncology settings.

In a real-world cohort of 300 patients with HER2-low metastatic breast cancer, T-DXd demonstrated a safety profile consistent with DESTINY-Breast04 in community oncology settings, with ILD/pneumonitis in 10% and toxicity-related discontinuation in 15%.

ctDNA-based next-generation sequencing in 236 patients with advanced breast cancer revealed frequent PIK3CA, TP53, and ESR1 mutations, highlighting key mechanisms of endocrine resistance with implications for targeted therapy selection.